Trading Update
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
5 January 2026
Q2 FY26 TRADING UPDATE: RECORD QUARTERLY AND HALF-YEAR
SALES
● Q2 FY26 revenue: $6.48 million – up 40.9% on PCP and 9.1% on Q1 FY26
● H1 FY26 revenue: $12.42 million – up 40.2% on PCP
Biome Australia Limited (ASX: BIO) is pleased to provide a trading update for Q2
FY26, reporting continued strong sales growth.
Q2 FY26 Performance
The Company achieved sales revenue of $6.48 million for Q2 FY26, representing
40.9% growth on the previous corresponding period (Q2 FY25: $4.6 million) and
9.1% sequential growth on Q1 FY26.
This result is particularly strong given Q2 is typically a seasonally softer period due
to reduced December trading days and the pharmacy channels focus on gifting
categories during the holiday season.
H1 FY26 Performance
Half-year sales revenue reached $12.42, representing 40.2% growth on the previous
corresponding period (H1 FY25: $8.86 million).
This performance reflects robust demand for Biome's clinically-proven probiotic
products.
-ENDS-
Approved for release by the Biome Australia Limited Board of Directors.
About Biome Australia Limited
Biome Australia develops, licenses, commercialises and markets innovative, evidence-
based live biotherapeutics (probiotics) and complementary medicines, many of which are
supported by clinical research. Biome aims to improve health outcomes and quality of life,
and make its products accessible to all.
Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with
some of the world's leading organisations in microbiome research and development,
Biome produced several unique live biotherapeutic (probiotic) products with innovative
delivery technologies that improve their stability and efficacy to create its flagship range of
complementary medicines: Activated Probiotics®
.
Supported by clinical research, including randomised double-blind placebo-controlled
trials, Activated Probiotics help prevent and support the management of various health
concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema
and IBS. Through practitioner-only distribution, Biome is committed to educating health
professionals on the newfound systemic health effects of the gut microbiota, helping them
to provide innovative, evidence-based natural medicines for the management of some of
humanity's most prevalent and chronic health concerns.
For more information visit: www.biomeaustralia.com
Investor Relations
Rechelle Friend
+61 (3) 9017 5800
corporate@biomeaustralia.com
Media enquiries
media@activated.co
Forward looking statements
This release may contain forward looking statements, including but not limited to projections,
guidance on future revenues, earnings, other potential synergies and estimates and the future
performance of Biome (Forward Looking Statements).
Forward Looking Statements are provided as a general guide only and should not be relied upon
as an indication or guarantee of future performance. Actual results, performance or achievements
may differ materially from those expressed or implied in such Forward Looking Statements and any
projections and assumptions on which these Forward Looking Statements are based. Such
statements may assume the success of Biome's business strategies. You are cautioned not to place
undue reliance on Forward Looking Statements.
The Forward Looking Statements are based on information available to Biome as at the date of this
release. Any Forward Looking Statements containing forward looking financial information
provided in this release is for illustrative purposes only and is not represented as being indicative of
Biome's views on its future financial condition and/or performance.
Nothing in this release is a promise or representation as to the future. No representation or warranty,
express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any
Forward Looking Statements contained in this release. Except as required by law or regulation
(including the ASX Listing Rules), Biome does not undertake to provide any additional or updated
information whether as a result of a change in expectations or assumptions, new information,
future events or results or otherwise.
To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in
respect of, and makes no representation or warranty, express or implied as to the fairness, currency,
accuracy, reliability or completeness of information in this release or the accuracy, likelihood of
achievement or reasonableness of any Forward Looking Statements (or any event or results
expressed or implied in any Forward Looking Statements) contained in, implied by, the information
in this release or any part of it, or that this release contains all material information about Biome or
which a prospective investor or purchaser may require in evaluating a possible investment in Biome
or acquisition of securities in Biome.
Investors are strongly cautioned not to place undue reliance on Forward Looking Statements,
particularly in light of the current economic climate and the significant volatility, uncertainty and
disruption caused by the Covid-19 pandemic.
Share your feedback
Discover